How Should Pharma Respond to the New Reality of Market Access in Germany, Prof. Dr. Thomas Hammerschmidt?

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with expert Prof. Dr. Thomas Hammerschmidt, to dive deep into Germany’s evolving AMNOG framework and what it really means for pharmaceutical pricing. 

This insightful conversation explores key changes in Germany’s pharma landscape, including the shift from negotiation-based pricing to benefit-linked guardrails, the 5% clinical trial rule, and their impact on innovation and reimbursement strategy. A must-listen for pharma professionals, health economists, and market access leaders!